Observational study of HR+/HER2- metastatic breast cancer patients treated with abemaciclib in Spain in the Named Patient Use Program (AbemusS).
Salvador BlanchJuan Miguel Gil-GilMiriam ArumíElena AguirreMiguel Ángel SeguíManuel AtienzaSilvia Díaz-CerezoAlberto MoleroJosé Manuel CerveraJoaquín GaviláPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2023)
These results suggest that abemaciclib is effective, as monotherapy and in combination, for patients with heavily pretreated mBC, consistent with clinical trial results.